Virtuix Partners with Rutgers to Explore AI-Driven Autism Therapy on Omni One
Rutgers University deployed Virtuix’s Omni One treadmill to research AI-assisted neurodivergent therapy and autism interventions using movement-centered XR and immersive behavioral analytics. The autism spectrum disorder treatment market is expected to expand from $9.2 billion in 2026 to over $18 billion by 2034 at a 9% CAGR.
1. Collaboration Overview
Rutgers University has deployed Virtuix’s Omni One omni-directional treadmill at WINLAB to research immersive full-body VR applications in neurodivergent therapy. This collaboration expands Virtuix’s platform beyond consumer and defense markets into healthcare and therapeutic research environments.
2. Research and Evaluation Focus
Researchers will integrate AI-enhanced virtual environments with movement-centered XR to develop autism interventions for children. The study will assess attention, movement patterns, response timing, engagement consistency and spatial interaction over time.
3. Market Opportunity and Outlook
The global autism treatment market is projected to grow from $9.2 billion in 2026 to over $18 billion by 2034 at a 9% CAGR. Success in these trials could position Virtuix to capture significant share in next-generation AI-enabled therapy solutions.